Vir Biotechnology, Inc.

BMV:VIR * Stock Report

Market Cap: Mex$22.5b

Vir Biotechnology Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BMV:VIR * Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Dec 24SellMex$12,782Vanina de VerneuilIndividual76Mex$168.19
01 Nov 24SellMex$202,833Vanina de VerneuilIndividual1,403Mex$144.57
11 Jun 24SellMex$807,223Sona Saira RamasastryIndividual4,000Mex$201.81
03 Apr 24SellMex$11,426,918Marianne De BackerIndividual72,995Mex$156.54
01 Apr 24SellMex$453,418Ann HanlyIndividual2,711Mex$167.25
27 Mar 24SellMex$981,593Sung LeeIndividual6,008Mex$163.38
22 Feb 24SellMex$1,727,584George ScangosIndividual10,028Mex$172.28
22 Feb 24SellMex$2,509,717Phillip PangIndividual14,568Mex$172.28
22 Feb 24SellMex$2,118,306Ann HanlyIndividual12,296Mex$172.28
16 Feb 24SellMex$580,389Phillip PangIndividual3,321Mex$174.76
16 Feb 24SellMex$1,901,076George ScangosIndividual10,878Mex$174.76

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VIR *?
Owner TypeNumber of SharesOwnership Percentage
Private Companies14,2710.0106%
Individual Insiders6,968,6785.18%
Public Companies8,550,9546.36%
General Public17,025,92512.7%
VC/PE Firms29,600,70422%
Institutions72,360,75353.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 74.26% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.4%
SoftBank Investment Advisers (UK) Limited
16,684,041Mex$2.8b0%0.87%
11.8%
BlackRock, Inc.
15,803,913Mex$2.6b13.1%no data
9.6%
Arch Venture Partners, L.P.
12,916,663Mex$2.2b0%10.26%
8.33%
The Vanguard Group, Inc.
11,200,666Mex$1.9b9.38%no data
6.36%
GSK plc
8,550,954Mex$1.4b0%no data
5.33%
State Street Global Advisors, Inc.
7,173,428Mex$1.2b32.4%no data
2.95%
Baillie Gifford & Co.
3,971,571Mex$663.4m-0.3%0.02%
2.78%
George Scangos
3,743,298Mex$625.3m0%no data
2.15%
AllianceBernstein L.P.
2,897,734Mex$484.0m5.31%0.01%
1.33%
Geode Capital Management, LLC
1,793,864Mex$299.6m6.1%no data
1.29%
Bridgeway Capital Management, LLC
1,730,770Mex$289.1m0%0.31%
1.16%
Bill & Melinda Gates Foundation Trust
1,559,142Mex$260.4m0%0.03%
1.09%
American Century Investment Management Inc
1,463,309Mex$244.4m-1.1%0.01%
1.01%
Renaissance Technologies LLC
1,354,400Mex$226.2m16%0.02%
0.98%
Vicki Sato
1,315,351Mex$219.7m0%no data
0.74%
Northern Trust Global Investments
998,553Mex$166.8m2.23%no data
0.65%
D. E. Shaw & Co., L.P.
880,231Mex$147.0m1,540%0.01%
0.64%
BNY Mellon Asset Management
858,281Mex$143.4m2.9%no data
0.54%
Norges Bank Investment Management
728,483Mex$121.7m0%no data
0.54%
Dimensional Fund Advisors LP
727,615Mex$121.5m-28.9%no data
0.54%
Bank of America Corporation, Asset Management Arm
725,409Mex$121.2m140%no data
0.54%
Charles Schwab Investment Management, Inc.
721,668Mex$120.5m13.3%no data
0.53%
Eaton Vance Management
718,927Mex$120.1m262%no data
0.53%
Jupiter Fund Management Plc
708,257Mex$118.3m41%0.02%
0.5%
Morgan Stanley, Investment Banking and Brokerage Investments
666,577Mex$111.3m39.2%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/11 14:47
End of Day Share Price 2023/09/13 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vir Biotechnology, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Huidong WangBarclays
Alec StranahanBofA Global Research